SCHEMBL1999633

SCHEMBL1999633

Cc1ccc2nc(Cc3c(Cl)cc(N)cc3Cl)sc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
RAB9A P51151 5/20 0.51
APP P05067 5/20 0.48
NPC1 O15118 5/20 0.48
KDM4E B2RXH2 2/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.41
SNCA P37840 1/20 0.40
AKR1B1 P15121 1/20 0.38
LMNA P02545 1/20 0.38
DYRK1A Q13627 1/20 0.38
KLF5 Q13887 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
KMT2A Q03164 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2003088 0.89 MAPT (0.48) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL2001974 0.86 APP (0.48) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL2000826 0.82 UBE2T (0.53) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL1996539 0.81 PTPN1 (0.47) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL11330644 0.81 RAB9A (0.59) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL27522825 0.79 RAB9A (0.49) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL2000214 0.78 LOXL2 (0.61) RAB9ANPC1GAASMN1; SMN2AKR1B1
SCHEMBL22059432 0.75 RAB9A (0.53) MAPTRAB9AAPPNPC1KDM4E
SCHEMBL1997399 0.75 PSMB8 (0.43) SMN1; SMN2AKR1B1LMNA
SCHEMBL26426430 0.75 RAB9A (0.56) MAPTRAB9AAPPNPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD MAPT 3145/4885RAB9A 1423/4885APP 3233/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD MAPT 3145/4885RAB9A 1423/4885APP 3233/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD MAPT 3145/4885RAB9A 1423/4885APP 3233/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD MAPT 3019/4885RAB9A 1869/4885APP 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.